Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58748 | 0.88 | GRM4 (0.45) | GRM4 | |
| SCHEMBL16522432 | 0.79 | GRM4 (0.36) | GRM4 | |
| SCHEMBL23660602 | 0.79 | GRM4 (0.36) | GRM4 | |
| SCHEMBL598853 | 0.78 | TSHR (0.46) | TSHRTDP1 | |
| SCHEMBL22628683 | 0.77 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL19607496 | 0.76 | GRM4 (0.31) | GRM4TDP1 | |
| SCHEMBL24569114 | 0.76 | GRM4 (0.35) | GRM4 | |
| SCHEMBL20616630 | 0.73 | — | — | |
| SCHEMBL5443031 | 0.72 | GRM4 (0.41) | GRM4 | |
| SCHEMBL14420440 | 0.72 | GRM4 (0.41) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149802-A1 | PERFLUOROPOLYETHER POLYMERS | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023183852-A9 | PHOSPHONATE PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023183852-A1 | PHOSPHONATE PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11738041-B2 | Proton-binding polymers for oral administration | RENOSIS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11332834-B2 | Catalyst and manufacturing method thereof | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-05-17 | — | — | US | disclosed |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-07-08 | — | — | US | disclosed |
| US-20200330625-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200138711-A1 | INJECTABLE HYDROGELS AND USES THEREOF | IHU STRASBOURG INSTITUT HOSPITALO-UNIVERSITAIRE DE STRASBOURG (FR) | 2020-05-07 | — | — | US | disclosed |
| WO-2020072681-A1 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS | AVIDEA TECHNOLOGIES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-16 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120123065-A1 | Hydrolytically Stable Maleimide-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| EP-0890570-A2 | Tertiary alkyl primary amines and process for preparing the same | ROHM AND HAAS COMPANY (US) | 1999-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | GRM4 4145/4885TSHR 4229/4885TDP1 719/4885 |
| US-20200138711-A1 | INJECTABLE HYDROGELS AND USES THEREOF | CUTA, CD44, PLOD3 | GRM4 4728/4885TSHR 2321/4885TDP1 3837/4885 |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | GRM4 1664/4885TSHR 2261/4885TDP1 2434/4885 |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | GRM4 3767/4885TSHR 726/4885TDP1 1997/4885 |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | PTMS, ANPEP, DNPEP | GRM4 4532/4885TSHR 1874/4885TDP1 1779/4885 |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | GRM4 1432/4885TSHR 4499/4885TDP1 293/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | GRM4 1524/4885TSHR 989/4885TDP1 2130/4885 |
| US-20200330625-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | ERAL1, TK2, PYCR1 | GRM4 1696/4885TSHR 789/4885TDP1 3002/4885 |
| US-11738041-B2 | Proton-binding polymers for oral administration | SLC9A1, HRH2, SLC9A2 | GRM4 2755/4885TSHR 1639/4885TDP1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.